Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
about
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegansVanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione storesPhosphorylation of profilin by ROCK1 regulates polyglutamine aggregationTransglutaminases: nature's biological gluesCystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Multiple Aspects of Gene Dysregulation in Huntington's DiseasePhysio-pathological roles of transglutaminase-catalyzed reactionsTissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's diseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and deathNo quiet surrender: molecular guardians in multiple sclerosis brainPossible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseasesCellular functions of tissue transglutaminaseDysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's diseaseThe Role of Interleukin-22 and Its Receptor in the Development and Pathogenesis of Experimental Autoimmune UveitisTissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanismsA novel hemostatic sealant composed of gelatin, transglutaminase and thrombin effectively controls liver trauma-induced bleeding in dogs.ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.Short time-series microarray analysis: methods and challenges.Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeatsIdentification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins.Therapeutic Strategies in Huntington's DiseaseGenetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infectionRNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptorsAutosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics.Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeastCystamine preparations exhibit anticoagulant activityInhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's diseaseTissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
P2860
Q21144448-64EC09B5-AF0F-4E07-8FF0-9303A5E0D072Q24308854-B8573280-E55B-4856-82C1-16D67D3D33FCQ24324878-2B1C53C2-103A-4FA5-B3BE-E9E17B0F6657Q24534936-8D11872A-7EEF-430A-9A01-813A4B1018C4Q24548047-37BB0BD2-E339-4121-B335-6CDC445B318BQ24605880-35058DA9-8122-4C70-86B0-B4EAD6FF756BQ24605961-20439FA7-9DFB-4FF7-A68D-8AD2C28C1EF3Q24618141-6C9C334B-4A42-48FF-8B02-39E5F26B90D4Q27005950-62A14368-D255-4BEA-92FA-7813731B973CQ28069852-6535284B-E8BF-499D-B91D-62CADB9FE85DQ28084633-3D2B3233-DFFA-43C6-BEC0-CC0B3757C391Q28248796-FE36F9E3-B245-44C9-9261-766DDB71ED91Q28260600-C9D6B444-4FB4-4194-8208-16548DCF8CD0Q28505492-B77D79C8-58FB-43B6-9F52-B13B5177C993Q28551977-68C5A0C6-234F-465F-8536-2960FD07173AQ28592026-3A937C0B-B146-4FA8-A4FB-BA1146FF3AD7Q30430562-3B3529CC-08DE-4359-B1FE-AC9DB72595A2Q30478632-FC439962-4691-4E75-85A2-CE836A2F8398Q30844932-B09C3166-7D49-40E4-A416-6537C61E7AA8Q31122113-05D44B9A-97BB-4566-8B5D-5759A877671DQ33370734-7D6CDBE4-E2D4-4B24-ABCD-6F8FF92B5DE2Q33635140-9C4ABBFB-34D7-4CAA-9D9D-6B6DF0216627Q33737470-5A0C6E68-F653-425D-AAC8-C66F56FBCE81Q33747446-2DB174E8-284E-4E53-8C4C-4EAFD155E712Q33790829-9AB1E954-591C-4D26-B015-29023D8B676DQ33793353-DC334EB9-CF48-47D0-BE2F-FF895C6ACEACQ33812932-25DBE140-66AE-449F-BD26-EC292624DE80Q33912442-FD654EF6-34CD-45C9-B86D-A56D2467D380Q33928419-F0FA145E-5130-4AD4-BC3D-32AA580D79B7Q33930636-5E7677D4-38E6-41D4-AC3B-AE995018775BQ33936969-3647F20A-1C68-48E6-9406-24C8A0EA144AQ34077018-8837A138-2402-44F0-8704-D5DC6ABED659Q34154776-E5E007E8-0F09-4FF1-9FBE-4AEF56D26EC8Q34281322-9C432281-976B-48D0-BA33-82394C68639CQ34323333-BE8F895D-3DDE-4B72-AC39-084DFD29CF9EQ34365610-0BC442EF-3C52-4CF5-99EE-BB33B72CAE2FQ34473794-443EA3D6-DF01-4780-9957-BA75B5232A2AQ34743269-B0AF3B05-F173-4F6E-B2E3-DA1C15F5AB05Q34763178-FE095D77-0B5B-44C6-890B-EB0268B6D616Q34763209-7CAE173E-4328-494C-9CCA-78984197AD86
P2860
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@en
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@nl
type
label
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@en
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@nl
prefLabel
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@en
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@nl
P2093
P356
P1433
P1476
Prolonged survival and decreas ...... utaminase inhibitor cystamine.
@en
P2093
Dennis Mitchell
Dorothee Chabas
Joe E Springer
Lawrence Steinman
Marcela V Karpuj
Mark W Becher
Rosetta Pedotti
Sawsan Youssef
P2888
P304
P356
10.1038/NM0202-143
P407
P577
2002-02-01T00:00:00Z
P5875
P6179
1043117163